Form 4: Agenus Inc. Director Jeynes-Ellis Awarded Stock Options

Director Allison Jeynes-Ellis received 5,000 stock options from Agenus Inc. on February 5, 2024, which will vest on February 5, 2025.

Summary

• Allison Jeynes-Ellis, a director of Agenus Inc., was granted 5,000 stock options on February 5, 2024.
• These options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.
• The options have an exercise price of $12.60 and will vest on February 5, 2025.
• The options expire on February 5, 2034.
• The grant was made prior to a 1 for 20 reverse stock split, representing 100,000 stock options with an exercise price of $0.63.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting period of one year incentivizes the director to contribute to the company's success over that time.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant is typical for a director-level position at a company of Agenus's size and market capitalization.
• Vesting schedules are also standard, with one-year vesting being a common practice.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates